Alto Neuroscience is redefining psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective medicines, helping patients get better faster. ​

Alto's Precision Psychiatry Platform™ measures biomarkers like EEG and wearable data, behavioral patterns, genetics, and other factors to match patients with the treatment they are most likely to respond to. Our approach matches the right patient with the right Alto drug based on AI-derived brain biomarkers, redefining psychiatry at a time when the world needs it most.

K2 HealthVentures

Tim Kendall

Risk and Return

What If Ventures

Windham Venture Partners

Able Partners

Apeiron Investment Group

Presight Capital

Korify Capital

Stanford University

NJF Capital

Gaingels

Alkeon Capital

Novartis Pharma

Lightswitch Capital

Sobrato Capital

Valor Equity Partners

Vine Ventures

Alpha Wave Ventures

Bioverge

InVivium Capital

Alexandria Venture Investments

Point72 Ventures

Eli Lilly

Franklin Templeton

Alto Neuroscience

To kick off this year’s #MeetTheTeam features, we’re showcasing Khanh Tang, Alto’s Associate Director of Clinical Operations. Khanh’s role is essential in reviewing data and metrics to support the oversight of current projects, as well as planning upcoming studies. When she’s not in the office, Khanh enjoys experiencing new places, cultures, and languages.


Our product candidates in development target core #brain processes, including:

🧠 Cognition
🙂 Emotion and its regulation
💤 Sleep and circadian rhythms

Learn more: https://brnw.ch/21wGjy5

#DYK that our clinical-stage pipeline includes novel drug candidates in #Depression, #PTSD, #Schizophrenia, and other #MentalHealth conditions? Learn more about our pipeline and target indications: https://brnw.ch/21wG7u9


#Psychiatry is an ever-changing field, and treatment options will continue to evolve in 2024. At Alto, we are passionate about developments in the #MentalHealth treatment landscape and furthering our mission to bring personalized, effective treatments to people in need.


Happy holidays from the Alto Team! We're planning to spend this holiday season prioritizing our mental health and spending some time with family and loved ones.


Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD. In addition, the company develops novel pharmacodynamically synergistic combinations and an AI-enabled biomarker platform that combine sources of information on patients brain activity and behavior to identify patients to respond to novel product candidates. Alto Neuroscience, Inc. was incorporated in 2019 and is based in Los Altos, California.

ANRO

COM:ALTONEUROSCIENCE

Alto Neuroscience

Last Close

4.27

21/11 19:40

Market Cap

338.20M

Beta: -

Volume Today

631.77K

Avg: -

Filings Not Available